Alexandra Balcom
CIK 1862147 · Chief Financial Officer · last filed 2026-06-03
Alexandra Balcom is a Chief Financial Officer who has filed 29 SEC Form 4 insider transactions across 2 companies since 2022. The most recent filing, for NUVL, was dated Jun 3, 2026. Across all open-market trades the lifetime net is −$29.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $10.6M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$10.57M
2
29
-$29.56M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NUVL | Chief Financial Officer | 85,733 | $123.25 | $10.57M | -$29.56M | 27 | 2026-06-03 |
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Director | — | $15.70 | — | $0 | 2 | 2026-06-03 |
Recent Filings
29 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-03 | NUVL | Mixed | — | -$1.05M | EDGAR |
| 2026-06-03 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2026-05-05 | NUVL | Mixed | — | -$1.09M | EDGAR |
| 2026-04-03 | NUVL | Mixed | — | -$1.19M | EDGAR |
| 2026-03-26 | NUVL | Mixed | −13,700 | -$2.45M | EDGAR |
| 2026-01-07 | NUVL | Mixed | +10,083 | -$721.3K | EDGAR |
| 2025-12-23 | NUVL | Exer (M) | +34,500 | $37.3K | EDGAR |
| 2025-12-10 | NUVL | Sell (S) | −7,084 | -$781.5K | EDGAR |
| 2025-11-19 | NUVL | Mixed | — | -$1.02M | EDGAR |
| 2025-10-17 | NUVL | Mixed | — | -$112.2K | EDGAR |